Reference
Gogia A, et al. Efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCH-P) in HER2-positive breast cancer: An Indian experience. Journal of Clinical Oncology 39 (Suppl. 15): 28 May 2021. Available from: URL: http://doi.org/10.1200/JCO.2021.39.15_suppl.e12619 [abstract]
Rights and permissions
About this article
Cite this article
Antineoplastics. Reactions Weekly 1869, 38 (2021). https://doi.org/10.1007/s40278-021-00903-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-00903-4